Following a comprehensive strategic review of its molded glass business, Gerresheimer, a system and solution provider and a global partner for the pharma, biotech and cosmetic industries, has decided to separate the business and intends to subsequently initiate a sales process for the business unit.
The aim of the strategic review was to evaluate various options for the best growth prospects and competitiveness of the molded glass business. The company now sees these outside the Gerresheimer Group. With the acquisition of Bormioli Pharma, Gerresheimer has formed a molded glass powerhouse with eight production plants across Europe, the Americas and Asia and a diversified product portfolio for the pharma, cosmetic, and food and beverage industries.
The molded glass business unit generated revenues of around 735 million Euros and an adjusted EBITDA margin of around 20% in 2024. The planned divestment is part of Gerresheimer’s extensive transformation into a system and solution provider purely for the pharma and biotech industry with a specialized portfolio of primary packaging and drug delivery systems.
“We see the best growth opportunities for our newly formed Moulded Glass Powerhouse outside the Gerresheimer Group,” explains Dietmar Siemssen, CEO of Gerresheimer AG. “As part of our strategic transformation, Gerresheimer will focus even stronger on the portfolio of systems and solutions for the pharma and biotech industry.”
Global molded glass powerhouse
The combined molded glass business of Gerresheimer and Bormioli Pharma comprises eight production plants in Germany, Belgium, Italy, the United States, and India. With around 3,700 employees, the business unit generated pro forma revenues of around 735 million Euros and an adjusted EBITDA margin of around 20% in the financial year 2024.
The Moulded Glass Powerhouse provides extensive expertise and global production capabilities for type I, II and III glass products, including decoration and customization. The diversified portfolio includes all kinds of glass packaging for the pharma, cosmetics, and food and beverage industries, such as bottles, containers, jars, and flacons.
Gerresheimer continuously invests in state-of-the-art technology for its glass production in all of the Moulded Glass plants. For example, the company has invested around 100 million Euros in an expansion and modernization project at its Moulded Glass site in Lohr am Main, Germany, over the past two years, installing a state-of-the-art, energy-efficient oxy-hybrid furnace.
Start of the separation of molded glass
As part of the integration of Bormioli Pharma into the Gerresheimer Group, Gerresheimer has begun to establish the combined molded glass business as a global, stand-alone Powerhouse. Today’s decision marks the beginning of the separation process. Subsequently the company intends to initiate a sales process. Gerresheimer will provide a further update at its upcoming Capital Markets Day on October 15, 2025.
Focus on pharma and biotech industry
The planned divestment of the molded glass business is another step in Gerresheimer’s transformation into a pure-play system and solution provider for the pharma and biotech industry with an increasing share of specific solutions for biologics and other high-value solutions.
By acquiring Bormioli Pharma, Gerresheimer has expanded its portfolio to include additional pharmaceutical primary packaging, closure solutions, accessories, and dosing systems, while also opening up new opportunities for system integration of high-value plastic solutions for the pharma and biotech industry.
